Subcutaneous contraceptive injections can be easily self-administered.
For more than 50 years, depot medroxyprogesterone acetate (DMPA) has been popular around the world as a 150-mg intramuscular (IM) injection. When used consistently, DMPA provides highly effective contraception; however, typically only half of women return to clinic for the required four shots per year. In the U.S., prefilled syringes intended for subcutaneous injection of DMPA have been available since 2004. Although subcutaneous DMPA is not FDA-approved for self-administration, this formulation provides lower peak levels and more stable blood levels at a lower dose of 104 mg.
A recent pharmacokinetic study of 150-mg IM DMPA showed that higher DMPA exposure, which likely delays return to fertility, appears to also be associated with greater …
Reviewing Author
DisclosuresConsultant/Advisory BoardPlanned Parenthood Federation of America
Grant/Research SupportSociety of Family Planning; California Department of Public Health Tobacco Control Program
Editorial BoardsContraception; Journal of General Internal Medicine
Leadership Positions in Professional SocietiesCouncil Member, Society of General Internal Medicine
DisclosuresConsultant/Advisory BoardPlanned Parenthood Federation of America
Grant/Research SupportSociety of Family Planning; California Department of Public Health Tobacco Control Program
Editorial BoardsContraception; Journal of General Internal Medicine
Leadership Positions in Professional SocietiesCouncil Member, Society of General Internal Medicine